LENZ Therapeutics (LENZ) Stock Analysis & Winston Score

LENZ Therapeutics is a small biotech company focused on eye care medicines. Its lead product is LNZ100, a eye drop designed to treat presbyopia, which is the age-related condition that makes it hard for people to read small text up close. The company targets adults over 40, a very large and growing patient population, and sells through eye care professionals. LENZ makes money by developing and eventually selling prescription eye drops, though as of now it is still in the clinical and early commercial stage and is not yet profitable — reflected in its deeply negative operating margin. The company operates primarily in the United States and is very small, with a market cap around $200 million. Its main competitive challenge is breaking into a market where larger, established eye care companies already have similar products, including Allergan's Vuity. The key risk is whether LENZ can gain enough commercial traction and physician adoption to build a sustainable business before it runs out of cash.